NeogenFRA:NG2 +5.08%68 FCF Yield % is 0.29 as of Jul. 11, 2026, which is 76% below its 10-year median of 1.21. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €10.73 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Neogen ranks better than 55.2% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Neogen's Trailing 12-Month Free Cash Flow is €5.1 Mil, and Market Cap is €1,838.8 Mil. Therefore, Neogen's FCF Yield % for today is 0.29%.
The historical rank and industry rank for Neogen's FCF Yield % or its related term are showing as below:
FRA:NG2'
s FCF Yield % Range Over the Past 10 Years
Min: -7.47 Med: 1.21 Max: 2.06
Current: 0.29
During the past 13 years, the highest FCF Yield % of Neogen was 2.06%. The lowest was -7.47%. And the median was 1.21%.
FRA:NG2's FCF Yield % is ranked better than 55.2% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.39
vs FRA:NG2: 0.29
Neogen's FCF Margin % for the quarter that ended in Feb. 2026 was 5.24%.
Neogen FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Neogen FCF Yield % Related Terms
Neogen FCF Yield % Historical Data
* Premium members only.
The historical data trend for Neogen's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NG2 vs UFPT, ALMR, BFLY: FCF Yield % Comparison
For the Medical Devices subindustry, Neogen's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Neogen's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (FRA:NG2) has a FCF Yield % of 0.29 as of Jul. 11, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Neogen and its competitors. This is 76% below median its historical median of 1.21. According to the industry distribution chart, Neogen ranks #383 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 44.8%.
Is Neogen's FCF Yield % too high?
Neogen's current FCF Yield % of 0.29 is 76% below median its 10-year median of 1.21. Based on the distribution chart, Neogen ranks #383 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's FCF Yield % compare to UFPT and ALMR?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #383 out of 855 companies for FCF Yield %. This puts Neogen in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Neogen and its competitors. Neogen's current FCF Yield % is 0.29, which is 76% below median its own 10-year median of 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.73, compared to a current price of €8.40 — trading 21.8% below its estimated fair value. The current FCF Yield % is 0.29, which is 76% below median its 10-year median of 1.21. Neogen's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Neogen (FRA:NG2), the current FCF Yield % is 0.29 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (FRA:NG2) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be undervalued.
The current stock price of €8.40 is trading 21.8% below its estimated GF Value™ of €10.73.
GuruFocus considers Neogen to be Modestly Undervalued.
Key valuation signals for FRA:NG2:
FCF Yield %: 0.29 (76% below median its 10-year median of 1.21)
GF Value™: €10.73 vs. price of €8.40 (21.8% below fair value)
No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score
Get the complete analysis for FRA:NG2
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NG2 has been successfully added to your 
